Serotype 6B pneumococcal meningitis in an immunocompetent infant immunized with heptavalent pneumococcal conjugated vaccine [5]

Clinical Infectious Diseases

Volumn 40, Issue 3, 2005, Pages 494-495

  Angoulvant, François ^a   Bidet, Philippe ^a   Doit, Catherine ^a   Aubertin, Guillaume ^a   Soussan, Valérie ^a   Bingen, Edouard ^a   Bourrillon, Antoine ^a   Paye, Albert ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPTAVALENT PNEUMOCOCCUS CONJUGATED VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL MENINGITIS; BRONCHIOLITIS; CASE REPORT; CHILD HOSPITALIZATION; DRUG CONTRAINDICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; LETTER; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE;

FEMALE; HUMANS; INFANT; MENINGITIS, PNEUMOCOCCAL; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; TREATMENT FAILURE;

EID: 13444260745     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427149     Document Type: Letter

References (8)

1. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95.
2. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362: 355-61.
3. Schmitt HJ, Faber J, Lorenz I, Schmole-Thoma B, Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (TVPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 2003; 21:3653-62.
4. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46.
5. Bingen E, Levy C, De La Rocque F, Aujard Y, Varon E, Boucherat M. Three-year multicenter pediatric surveillance of pneumococcal meningitis in France. In: Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC) [abstract G-531]. Washington, DC: American Society for Microbiology, 2004.
6. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenichy of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 1998; 101: 604-11.
7. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35.
8. Jette LP, Delage G, Ringuette L, et al. Surveillance of invasive Streptococcus pneumoniae infection in the province of Quebec, Canada, from 1996 to 1998: serotype distribution, antimicrobial susceptibility, and clinical characteristics. J Clin Microbiol 2001; 39:733-7.